Table 3.

iPSC-derived RPE-based studies for inherited and non-inherited macular degenerations. Study type: Observational. Last updated 25 October 2016.

Sponsor	Cell Type	Condition	ClinicalTrials.gov Identifier	Status	Objective
Moorfields Eye Hospital	Human iPSC-derived RPE	Age-related macular degeneration	NCT02464956	Not yet recruiting	Successful production of a retinal epithelial layer of cells that fulfills Regulatory Regulation for Transplantation.
NHS Foundation Trust
Mayo Clinic	Human iPSC-derived RPE	Autosomal recessive bestrophinopathy (ARB)	NCT02162953	Recruiting	To collect DNA, RNA, and skin samples from individuals with ARB or other diseases due to mutations in the gene BEST1. These models will be used to identify and test therapeutic approaches to treating these diseases.
		Best vitelliform macular dystrophy (BVMD)
		Adult-onset vitelliform dystrophy (AVMD)
		Autosomal dominant vitreoretinalchoroidopathy (ADVIRC)
		Retinitis pigmentosa (RP)
National Eye Institute (NEI)	Human iPSC-derived RPE		NCT01432847	Recruiting	To collect hair, skin, and blood samples to study three eye diseases that affect the retina (Best disease, L-ORD, and AMD)

iPSC, induced pluripotent stem cell; RPE, retinal pigment epithelium; NHS, National Health Service (of England); ARB, angiotensin receptor blockers; L-ORD, late-onset retinal degeneration; AMD, age-related macular degeneration.